Continue reading this on our app for a better experience

Open in App
Floating Button
Home Capital Company in the news

Hyphens Pharma launches Ceradan Advanced

Samantha Chiew
Samantha Chiew • 1 min read
Hyphens Pharma launches Ceradan Advanced
SINGAPORE (July 10): Hyphens Pharma International has launched its so-called "next generation" Ceradan cream.
Font Resizer
Share to Whatsapp
Share to Facebook
Share to LinkedIn
Scroll to top
Follow us on Facebook and join our Telegram channel for the latest updates.

SINGAPORE (July 10): Hyphens Pharma International has launched its so-called "next generation" Ceradan cream.

Ceradan Advanced is the group’s latest product that targets the needs of those suffering from eczema.

It comprises a new formula that is able to maintain a lower skin pH for a longer time – up to 12 hours.

Its lower pH also allows for the restoration of the skin barrier against environmental insults.

Currently, Ceradan Advanced’s formula is patent-pending and will be available in clinics and retail pharmacies in hospitals.

Meanwhile, the group will be extending its existing Ceradan emollient to pharmacy chains in Singapore.

Lim See Wah, executive chairman and CEO of Hyphens Pharma, says, “We will be working closely with doctors who will appreciate the benefit of this advanced skin buffering system, availing the product to help patients who seek medical attention. We will also now expand the access of our current Ceradan range through the OTC channels, making Ceradan readily available to consumers.”


See: Hyphens Pharma gears up for growth with product pipeline, Vietnam focus

Shares in Hyphens Pharma closed 2.44% higher on Wednesday at 21 cents.

Highlights

Re test Testing QA Spotlight
1000th issue

Re test Testing QA Spotlight

Get the latest news updates in your mailbox
Never miss out on important financial news and get daily updates today
×
The Edge Singapore
Download The Edge Singapore App
Google playApple store play
Keep updated
Follow our social media
© 2024 The Edge Publishing Pte Ltd. All rights reserved.